JHVEPhoto/iStock Editorial through Getty Pictures
- Fresenius (OTCPK:FSNUF) stated on Wednesday that the FDA has accredited its Biologics License Software for 2 denosumab biosimilars, Conexxence and Bomyntra, developed by its working firm Fresenius Kabi.
- These biosimilars are actually licensed for all accredited makes use of of their reference
